2022
Acute kidney injury due to myoglobin cast nephropathy in the setting of coronavirus disease 2019-mediated rhabdomyolysis: a case report
Tuan J, Ogbuagu O, Kumar D, Altice F, Fikrig M. Acute kidney injury due to myoglobin cast nephropathy in the setting of coronavirus disease 2019-mediated rhabdomyolysis: a case report. Journal Of Medical Case Reports 2022, 16: 491. PMID: 36578087, PMCID: PMC9795945, DOI: 10.1186/s13256-022-03721-z.Peer-Reviewed Case Reports and Technical NotesConceptsAcute kidney injuryCoronavirus disease 2019Kidney injuryDisease 2019Cast nephropathyEnd-organ damageRenal biopsy findingsSpectrum of diseaseBaseline 6Gastrointestinal symptomsHospital courseBiopsy findingsCase presentationAPoor appetiteRenal failureRenal functionOral intakeUrine outputInitial diagnosisCaucasian manCase reportRhabdomyolysisNephropathyAbnormal tasteOrgan systems
2021
An expanding HIV epidemic among older adults in Ukraine: Implications for patient-centered care
Rozanova J, Zeziulin O, Rich KM, Altice FL, Kiriazova T, Zaviryukha I, Sosidko T, Gulati K, Carroll C, Shenoi SV. An expanding HIV epidemic among older adults in Ukraine: Implications for patient-centered care. PLOS ONE 2021, 16: e0256627. PMID: 34591848, PMCID: PMC8483339, DOI: 10.1371/journal.pone.0256627.Peer-Reviewed Original ResearchConceptsStandardized mortality ratioMortality rateCause standardized mortality ratioTime of diagnosisGeneral population ratesLate-stage HIVAge-matched groupHigh mortality ratePatient-centered careIncident HIVHIV diagnosisHIV testingHIV incidenceHIV treatmentHIV epidemicMortality ratioTreatment strategiesGeneral populationHIVMortality trendsAge groupsEECA countriesTreatment programSame calendar yearOlder peopleAssociation Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
Domingo P, Mur I, Mateo G, Gutierrez M, Pomar V, de Benito N, Corbacho N, Herrera S, Millan L, Muñoz J, Malouf J, Molas M, Asensi V, Horcajada J, Estrada V, Gutierrez F, Torres F, Perez-Molina J, Fortun J, Villar L, Hohenthal U, Marttila H, Vuorinen T, Nordberg M, Valtonen M, Frigault M, Mansour M, Patel N, Fernandes A, Harvey L, Foulkes A, Healy B, Shah R, Bensaci A, Woolley A, Nikiforow S, Lin N, Sagar M, Shrager H, Huckins D, Axelrod M, Pincus M, Fleisher J, Lampa J, Nowak P, Vesterbacka J, Rasmuson J, Skorup P, Janols H, Niward K, Chatzidionysiou K, Asgeirsson H, Parke Å, Blennow O, Svensson A, Aleman S, Sönnerborg A, Henter J, Horne A, Al-Beidh F, Angus D, Annane D, Arabi Y, Beane A, Berry S, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Cheng A, Cove M, De Jong M, Derde L, Estcourt L, Goossens H, Gordon A, Green C, Haniffa R, Ichihara N, Lamontagne F, Lawler P, Litton E, Marshall J, McArthur C, McAuley D, McGuinness S, McVerry B, Montgommery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Reyes F, Rowan K, Saito H, Santos M, Seymour C, Shankar-Hari M, Turgeon A, Turner A, van Bentum-Puijk W, van de Veerdonk F, Webb S, Zarychanski R, Baillie J, Beasley R, Cooper N, Fowler R, Galea J, Hills T, King A, Morpeth S, Netea M, Ogungbenro K, Pettila V, Tong S, Uyeki T, Youngstein T, Higgins A, Lorenzi E, Berry L, Salama C, Rosas I, Ruiz-Antorán B, Muñez Rubio E, Ramos Martínez A, Campos Esteban J, Avendaño Solá C, Pizov R, Sanz Sanz J, Abad-Santos F, Bautista-Hernández A, García-Fraile L, Barrios A, Gutiérrez Liarte Á, Alonso Pérez T, Rodríguez-García S, Mejía-Abril G, Prieto J, Leon R, VEIGA V, SCHEINBERG P, FARIAS D, PRATS J, CAVALCANTI A, MACHADO F, ROSA R, BERWANGER O, AZEVEDO L, LOPES R, DOURADO L, CASTRO C, ZAMPIERI F, AVEZUM A, LISBOA T, ROJAS S, COELHO J, LEITE R, CARVALHO J, ANDRADE L, SANDES A, PINTÃO M, SANTOS S, ALMEIDA T, COSTA A, GEBARA O, FREITAS F, PACHECO E, MACHADO D, MARTIN J, CONCEIÇÃO F, SIQUEIRA S, DAMIANI L, ISHIHARA L, SCHNEIDER D, DE SOUZA D, Hermine O, Mariette X, Tharaux P, Resche Rigon M, Porcher R, Ravaud P, Azoulay E, Cadranel J, Emmerich J, Fartoukh M, Guidet B, Humbert M, Lacombe K, Mahevas M, Pene F, Pourchet-Martinez V, Schlemmer F, Tibi A, Yazdanpanah Y, Dougados M, Bureau S, Horby P, Landray M, Baillie K, Buch M, Chappell L, Day J, Faust S, Haynes R, Jaki T, Jeffery K, Juszczak E, Lim W, Mafham M, Montgomery A, Mumford A, Thwaites G, Kamarulzaman A, Syed Omar S, Ponnampalavanar S, Raja Azwa R, Wong P, Kukreja A, Ong H, Sulaiman H, Basri S, Ng R, Megat Johari B, Rajasuriar R, Chong M, Neelamegam M, Syed Mansor S, Zulhaimi N, Lee C, Altice F, Price C, Malinis M, Hasan M, Wong C, Chidambaram S, Misnan N, Mohd Thabit A, Sim B, Bidin F, Mohd Abd Rahim M, Saravanamuttu S, Tuang W, Mohamed Gani Y, Thangavelu S, Tay K, Ibrahim N, Halid L, Tan K, Mukri M, Arip M, Koh H, Syed Badaruddin S, Raja Sureja L, Chun G, TORRE-CISNEROS J, MERCHANTE N, LEON R, CARCEL S, GARRIDO J, Galun E, Soriano A, Martínez J, Castán C, Paredes R, Dalmau D, Carbonell C, Espinosa G, Castro P, Muñóz J, Almuedo A, Prieto S, Pacheco I, Ratain M, Pisano J, Strek M, Adegunsoye A, Karrison T, Jozefien D, Karel F.A. V, Elisabeth D, Cedric B, Bastiaan M, Shankar-Hari M, Vale C, Godolphin P, Fisher D, Higgins J, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty J, Berry L, Broman N, Cavalcanti A, Colman R, De Buyser S, Derde L, Domingo P, Omar S, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon A, Haynes R, Hermine O, Horby P, Horick N, Kumar K, Lambrecht B, Landray M, Leal L, Lederer D, Lorenzi E, Mariette X, Merchante N, Misnan N, Mohan S, Nivens M, Oksi J, Perez-Molina J, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan A, Ravaud P, Reid P, Rutgers A, Sancho-Lopez A, Seto T, Sivapalasingam S, Soin A, Staplin N, Stone J, Strohbehn G, Sunden-Cullberg J, Torre-Cisneros J, Tsai L, van Hoogstraten H, van Meerten T, Veiga V, Westerweel P, Murthy S, Diaz J, Marshall J, Sterne J. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA 2021, 326: 499-518. PMID: 34228774, PMCID: PMC8261689, DOI: 10.1001/jama.2021.11330.Peer-Reviewed Original ResearchConceptsIL-6 antagonistsUsual careCause mortalitySummary odds ratiosOdds ratioEligible trialsMechanical ventilationClinical trialsMortality riskSecondary infectionCOVID-19Primary outcome measureAbsolute mortality riskBias assessment toolRisk of biasStudy selection criteriaCochrane riskSecondary outcomesI2 statisticPlaceboOutcome measuresMAIN OUTCOMEPatientsAdditional trialsPrimary analysis
2020
Response to the COVID-19 Outbreak in Urban Settings in China
Ni Z, Lebowitz ER, Zou Z, Wang H, Liu H, Shrestha R, Zhang Q, Hu J, Yang S, Xu L, Wu J, Altice FL. Response to the COVID-19 Outbreak in Urban Settings in China. Journal Of Urban Health 2020, 98: 41-52. PMID: 33258088, PMCID: PMC7703725, DOI: 10.1007/s11524-020-00498-8.Peer-Reviewed Original ResearchTocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes
2018
Brief Report
Delaney JA, Nance RM, Whitney BM, Altice FL, Dong X, Trejo MEP, Matsuzaki M, Taxman FS, Chander G, Kuo I, Fredericksen R, Strand LN, Eron JJ, Geng E, Kitahata MM, Mathews WC, Mayer K, Moore RD, Saag MS, Springer S, Chandler R, Kahana S, Crane HM. Brief Report. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 283-287. PMID: 30036277, PMCID: PMC6681811, DOI: 10.1097/qai.0000000000001803.Peer-Reviewed Original ResearchConceptsPHQ-9 scoresDepressive symptomsSubstance useATS useLower oddsMean decreaseAmphetamine-type substancesAIDS Research NetworkCocaine/crack useDepressive symptom scoresMental health disordersJoint longitudinal-survival modelCocaine/crackPoor outcomeSymptom scoresPHQ-9Health disordersIllicit opiatesSymptomsPLWHLongitudinal assessmentSite cohortSubstance use frequencyCrack useAbstinenceOpioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine
Mazhnaya A, Marcus R, Bojko MJ, Zelenev A, Makarenko I, Pykalo I, Filippovych S, Dvoriak S, Altice FL. Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 288-295. PMID: 30312275, PMCID: PMC8215524, DOI: 10.1097/qai.0000000000001827.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentHIV treatment cascadeTreatment cascadeAgonist treatmentIndependent factorsHepatitis C virus testingOpioid-dependent PWIDOpioid use disorderClinical care settingsLogistic regression modelsOAT coverageAntiretroviral therapyHIV careUNAIDS 90HIV preventionImproved outcomesTreatment strategiesCare settingsVirus testingNationwide studyPWIDUse disordersOAT expansionHIVCareIncarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, Trickey A, Abbott S, Strathdee SA, Abramovitz D, Maher L, Iversen J, Bruneau J, Zang G, Garfein RS, Yen YF, Azim T, Mehta SH, Milloy MJ, Hellard ME, Sacks-Davis R, Dietze PM, Aitken C, Aladashvili M, Tsertsvadze T, Mravčík V, Alary M, Roy E, Smyrnov P, Sazonova Y, Young AM, Havens JR, Hope VD, Desai M, Heinsbroek E, Hutchinson SJ, Palmateer NE, McAuley A, Platt L, Martin NK, Altice FL, Hickman M, Vickerman P. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. The Lancet Infectious Diseases 2018, 18: 1397-1409. PMID: 30385157, PMCID: PMC6280039, DOI: 10.1016/s1473-3099(18)30469-9.Peer-Reviewed Original ResearchConceptsHCV acquisition riskAcquisition riskHCV incidenceModerate heterogeneitySystematic reviewHepatitis C virus acquisitionHepatitis C virus infectionHIV acquisition riskRisk of HCVC virus infectionNewcastle-Ottawa ScaleRisk of biasRisk of HIVNational InstituteCommunity-recruited PWIDOutcomes of interestIncident infectionsCohort studyHIV acquisitionHIV transmissionHigh prevalenceVirus infectionRecent incarcerationExclusion criteriaHigh riskAge-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review
Kinner SA, Snow K, Wirtz AL, Altice FL, Beyrer C, Dolan K. Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review. Journal Of Adolescent Health 2018, 62: s18-s26. PMID: 29455713, PMCID: PMC7413042, DOI: 10.1016/j.jadohealth.2017.09.030.Peer-Reviewed Original ResearchConceptsHepatitis CHepatitis BRelative riskOlder prisonersGlobal prevalencePrevalence estimatesSystematic reviewPrevalence of HIVAge-specific prevalence estimatesAge-specific prevalenceIncidence of infectionActive tuberculosisPooled prevalenceLow prevalenceHIVPrevalenceInfectionYoung adultsTuberculosisAge categoriesIncarcerated populationsAYAsIncarcerated adolescentsIncarcerated peopleCustodial settings
2017
Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study
Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. The Lancet Infectious Diseases 2017, 18: 215-224. PMID: 29153265, PMCID: PMC5860640, DOI: 10.1016/s1473-3099(17)30676-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntiviral AgentsChemopreventionCitiesComputer SimulationDisease Transmission, InfectiousFemaleHepatitis CHumansMaleMiddle AgedModels, StatisticalPrevalenceSubstance Abuse, IntravenousSurveys and QuestionnairesTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsBaseline HCV prevalenceHepatitis C virusHCV prevalenceInjection partnersPrevention strategiesTreatment coverageTransmission of HCVHepatitis C virus (HCV) treatmentHCV elimination strategySuccessful HCV treatmentC virus treatmentInjection drug usersHCV treatment coverageAdditional network memberHCV treatmentActing antiviralsC virusChronic infectionVirus treatmentDrug usersPrevalenceDrug abuseDrugsNational InstitutePreventionPrevalence of Human Immunodeficiency Virus and Sexually Transmitted Infections Among Cisgender and Transgender Women Sex Workers in Greater Kuala Lumpur, Malaysia
Wickersham JA, Gibson BA, Bazazi AR, Pillai V, Pedersen CJ, Meyer JP, El-Bassel N, Mayer KH, Kamarulzaman A, Altice FL. Prevalence of Human Immunodeficiency Virus and Sexually Transmitted Infections Among Cisgender and Transgender Women Sex Workers in Greater Kuala Lumpur, Malaysia. Sexually Transmitted Diseases 2017, 44: 663-670. PMID: 28708696, PMCID: PMC5636657, DOI: 10.1097/olq.0000000000000662.Peer-Reviewed Original ResearchConceptsTransgender women sex workersHuman immunodeficiency virusInconsistent condom useCisgender women sex workersHIV prevalenceImmunodeficiency virusSex workersWomen sex workersDrug useCondom useHigh human immunodeficiency virusGlobal HIV prevalenceLast HIV testLifetime HIV testingPooled HIV prevalenceRespondent-driven samplingSTI prevalenceHIV testHIV burdenHIV testingMedian timeSTI preventionΧ testChlamydia trachomatisIndependent sample t-testImproving correctional healthcare providers' ability to care for transgender patients: Development and evaluation of a theory-driven cultural and clinical competence intervention
Hughto J, Clark KA, Altice FL, Reisner SL, Kershaw TS, Pachankis JE. Improving correctional healthcare providers' ability to care for transgender patients: Development and evaluation of a theory-driven cultural and clinical competence intervention. Social Science & Medicine 2017, 195: 159-169. PMID: 29096945, PMCID: PMC5712271, DOI: 10.1016/j.socscimed.2017.10.004.Peer-Reviewed Original ResearchConceptsCorrectional healthcare providersGender-affirming careTransgender patientsHealthcare providersClinical competenceTransgender careTransgender cultural competenceFuture efficacy testingLinear mixed-effects regression modelsHealthcare providers' abilityQualitative exit interviewsMixed effects regression modelsGroup-based interventionHormone therapyPatientsProviders' willingnessTransgender womenStudy outcomesExit interviewsCareEfficacy testingInterventionProviders' abilityEffects regression modelsConfidential surveyMeasuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users
Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, Copenhaver M. Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. AIDS And Behavior 2017, 22: 1228-1238. PMID: 28695388, PMCID: PMC5762432, DOI: 10.1007/s10461-017-1851-1.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisSex-related risk behaviorsHigh-risk drug usersAcceptability of PrEPHigh-risk PWUDPrimary HIV preventionHIV prevention approachesDrug treatment settingsKey risk populationsHIV-negative PWUDHigh acceptabilityHIV clinicPrEP acceptabilityHIV testingPrEP uptakeMethadone clinicsHIV preventionRisk populationsSide effectsTreatment settingsDrug usersPrEP attributesRisk behaviorsPrEPUnderserved populationsHousing Experiences among Opioid-Dependent, Criminal Justice-Involved Individuals in Washington, D.C.
Wooditch A, Mbaba M, Kiss M, Lawson W, Taxman F, Altice FL. Housing Experiences among Opioid-Dependent, Criminal Justice-Involved Individuals in Washington, D.C. Journal Of Urban Health 2017, 95: 61-70. PMID: 28550643, PMCID: PMC5862691, DOI: 10.1007/s11524-017-0156-z.Peer-Reviewed Original ResearchConceptsSelf-reported criminal activityResidential mobilityCriminal activityCriminal justice-involved individualsDrug/alcohol useCriminal justice involvementJustice-involved individualsHousing experiencesHousing transitionsHousing contributesTreatment-seeking opioid usersHousing settingsCriminal involvementCriminal offensesCriminal behaviorJustice involvementHousing typeHousing statusHousing facilitiesSocial networksIndividual's likelihoodLittle researchSubstance useAlcohol useCrimeCohort profile: seek, test, treat and retain United States criminal justice cohort
Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort profile: seek, test, treat and retain United States criminal justice cohort. Substance Abuse Treatment, Prevention, And Policy 2017, 12: 24. PMID: 28511680, PMCID: PMC5433052, DOI: 10.1186/s13011-017-0107-4.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsTreatment cascadeViral loadHIV RNA viral loadCD4 T-cell countRisk behaviorsSubstance useT-cell countsHepatitis C infectionRNA viral loadInjection drug useHealth Related QualityHIV treatment cascadeUnprotected sexual intercourseHealth care accessRecent polysubstance useC infectionViral suppressionHIV diagnosisHIV infectionMedian ageRelated qualityCriminal justice involvementART treatmentCohort members
2016
Healthcare resources are inadequate to address the burden of illness among HIV-infected male prisoners in Malaysia
Bick J, Culbert G, Al-Darraji HA, Koh C, Pillai V, Kamarulzaman A, Altice F. Healthcare resources are inadequate to address the burden of illness among HIV-infected male prisoners in Malaysia. International Journal Of Prisoner Health 2016, 12: 253-269. PMID: 27921633, DOI: 10.1108/ijph-06-2016-0017.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHealth needsLatent tuberculosis infectionCo-morbid conditionsBurden of illnessComprehensive health assessmentHepatitis C virusComplex health needsSerious public health threatPublic health threatCD4 monitoringHIV careTuberculosis infectionHIV statusPhysical examinationC virusUntreated syphilisMale prisonersTobacco useHIVDisease comorbiditiesMalaysian adultsStructured historyHealthcare resourcesDrug useElbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Annals Of Internal Medicine 2016, 165: 625-634. PMID: 27537841, DOI: 10.7326/m16-0816.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntiviral AgentsBenzofuransBuprenorphineBuprenorphine, Naloxone Drug CombinationDouble-Blind MethodDrug CombinationsDrug Resistance, ViralFemaleGenotypeHepatitis C, ChronicHumansImidazolesMaleMedication AdherenceMethadoneMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersQuinoxalinesRecurrenceSubstance Abuse, IntravenousYoung AdultConceptsDeferred-treatment groupOpioid agonist therapyImmediate treatment groupHepatitis C virus infectionC virus infectionElbasvir-grazoprevirDrug useProbable reinfectionAgonist therapyHCV infectionViral recurrenceAdverse eventsVirus infectionChronic HCV genotype 1Double-blind trialGenotype 3 infectionTreatment-naive patientsHCV genotype 1Interferon-free HCV treatmentOngoing drug useVirologic responseHCV therapyHCV treatmentPrimary outcomeGenotype 1Intersecting epidemics of HIV, HCV, and syphilis among soon-to-be released prisoners in Kyrgyzstan: Implications for prevention and treatment
Azbel L, Polonsky M, Wegman M, Shumskaya N, Kurmanalieva A, Asanov A, Wickersham JA, Dvoriak S, Altice FL. Intersecting epidemics of HIV, HCV, and syphilis among soon-to-be released prisoners in Kyrgyzstan: Implications for prevention and treatment. International Journal Of Drug Policy 2016, 37: 9-20. PMID: 27455177, PMCID: PMC5124506, DOI: 10.1016/j.drugpo.2016.06.007.Peer-Reviewed Original ResearchConceptsDrug injectionHIV infectionLifetime drug injectionPrison drug injectionHIV care continuumAntiretroviral therapy coverageConfidence intervalsMean numberEpidemic of HIVHealth assessment surveyUndiagnosed syphilisSyphilis infectionConsented participantsHIV incidenceHIV transmissionIndependent correlatesWeighted prevalenceEvidence-based responsesHIV epidemicCare continuumDuration of imprisonmentHIV preventionHealth SurveyAIDS mortalityHIV
2015
Patterns of substance use and correlates of lifetime and active injection drug use among women in Malaysia
Wickersham JA, Loeliger KB, Marcus R, Pillai V, Kamarulzaman A, Altice FL. Patterns of substance use and correlates of lifetime and active injection drug use among women in Malaysia. The American Journal Of Drug And Alcohol Abuse 2015, 42: 98-110. PMID: 26636885, PMCID: PMC4837957, DOI: 10.3109/00952990.2015.1101467.Peer-Reviewed Original ResearchConceptsNeedle-syringe exchange programsDrug injectionCorrelates of lifetimeDrug usePolysubstance useInjection-related risk behaviorsActive injection drug useSelf-reported HIV statusAgonist maintenance therapyLifetime drug injectionOpioid/benzodiazepineSubstance useInjection drug useHarm reduction servicesDrug use historyHarm reduction measuresPrior criminal justice involvementOAT servicesMaintenance therapyOpioid useHIV statusHIV transmissionRisk factorsCriminal justice involvementHIV riskPrevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational Study
Lincoln T, Simon-Levine D, Smith J, Donenberg GR, Springer SA, Zaller N, Altice FL, Moore K, Jordan AO, Draine J, Desabrais M. Prevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational Study. Journal Of Correctional Health Care 2015, 21: 125-139. PMID: 25788608, PMCID: PMC4433291, DOI: 10.1177/1078345815574566.Peer-Reviewed Original ResearchConceptsEmotional distressJail detaineesSeverity Index scoreAddiction Severity Index (ASI) scoresPoor physical healthMental health assessmentHIV/AIDSEmotional distress scoresObservational studyIndex scoreDistress scoresHealth servicesHealth RankingsSubstance abusePhysical healthJail systemHealth assessmentBisexual orientationSpecific correlatesDistressFamily supportPrevalenceScoresHigh levelsPLWHA